Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early

Dow Jones02-25 23:56

By Chris Wack

Celldex Therapeutics shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance.

The company said 1,939 patients were enrolled in 43 countries and more than 500 sites.

Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

February 25, 2026 10:56 ET (15:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614394460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614394460","market":"fut","top_or_hot":-1,"title":"Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance. \n</p>\n<p>\n  The company said 1,939 patients were enrolled in 43 countries and more than 500 sites. \n</p>\n<p>\n  Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 10:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelldex Shares Rise After Barzolvolimab Study Completes Enrollment Early\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-25 23:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance. \n</p>\n<p>\n  The company said 1,939 patients were enrolled in 43 countries and more than 500 sites. \n</p>\n<p>\n  Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 10:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLDX","symbol_name":"塞德斯医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614394460","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614394460","pubTimestamp":1772034960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Celldex Therapeutics shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance.The company said 1,939 patients were enrolled in 43 countries and more than 500 sites.Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLDX":"塞德斯医疗","BK4139":"生物科技"},"translate_title":"Barzolvolimab研究提前完成入组后Celldex股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Celldex Therapeutics shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance. \n\n\n  The company said 1,939 patients were enrolled in 43 countries and more than 500 sites. \n\n\n  Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 10:56 ET (15:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614394460","isCrawlerRequest":true}